The dynamic landscape of Acute Coronary Syndrome (ACS) management has experienced significant advancements over the past decade. This article aims to provide a comprehensive overview of these advancements and best practices.
Advances in pharmacotherapy have been pivotal in ACS management. Novel antiplatelet agents such as Ticagrelor and Prasugrel have shown superior efficacy compared to traditional drugs, reducing the risk of recurrent ischemic events. Additionally, the advent of high-sensitivity cardiac troponin assays has improved early detection and risk stratification of ACS.
Early identification and risk stratification using the GRACE and TIMI risk scores remain crucial. Rapid initiation of dual antiplatelet therapy (DAPT) and anticoagulation therapy, followed by early invasive strategies (coronary angiography and revascularization), are recommended. High-risk patients benefit from early revascularization, while conservative strategies may be suitable for low-risk patients.
Cardiac rehabilitation plays a significant role in secondary prevention. It includes patient education, exercise training, diet counseling, and psychosocial support. Participation in cardiac rehabilitation programs has been associated with improved outcomes and reduced mortality in ACS patients.
Future research should focus on refining risk stratification tools, developing novel therapeutic agents, and optimizing the timing and selection of invasive strategies. Personalized medicine, considering genetics and comorbidities, will play an increasing role in ACS management.
Effective management of ACS requires a multifaceted approach, encompassing rapid diagnosis, risk stratification, prompt initiation of therapy, and comprehensive cardiac rehabilitation. The integration of recent advancements into clinical practice, coupled with adherence to evidence-based guidelines, will ensure optimal patient outcomes in ACS.
1.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
2.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Treating Depression: Crucial for Recovery From Fibromyalgia
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Immune Regulation of Blood Cell Development
3.
Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health
4.
Transformative Frameworks in Oncology for Better Care
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation